+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06542250

Open-label Phase III Study of AZD5492, a T Cell-engaging Antibody Targeting CD20, in Adults With Relapsed or Refractory B-Cell Malignancies

Led by AstraZeneca · Updated on 2026-09-30

174

Participants Needed

31

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AZD5492, an experimental T cell-engaging antibody targeting CD20, in people with relapsed or refractory B-cell malignancies. This Phase III trial aims to assess whether AZD5492 is safe, tolerable, and effective in treating these cancers. The study focuses on participants who have undergone at least two prior treatments and have specific types of mature B-cell neoplasms such as large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. Participants will receive AZD5492 as a monotherapy administered subcutaneously. The study follows a sequential design with dose escalation and dose expansion modules to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy. Treatment continues with monitoring during the treatment period and up to 90 days after the last dose, with follow-up extending to two years to observe response rates and survival outcomes. During the trial, participants will have regular assessments including safety evaluations for adverse events and dose-limiting toxicities, pharmacokinetic blood tests to measure drug levels, and monitoring of immune response to the drug. Researchers will measure clinical outcomes such as overall response rate, complete response rate, duration of response, progression-free survival, and overall survival. The total participation duration may last up to two years after the last dose for long-term effectiveness and safety monitoring.

CONDITIONS

Brief Title

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here